Recent breakthroughs in HCV treatment, namely the highly efficacious oral direct-acting antiviral (DAA) therapy, have opened opportunities for controlling HCV infection, reducing burden and cost of managing liverrelated conditions, and even elimination of HCV as a public health concern. 9 Importantly, treatment of chronic infection will reduce the pool of infected persons, thereby preventing further transmission.
The World Health Organization (WHO) has recently formulated the "Global Health Sector Strategy on Viral Hepatitis, 2016-2021" 10 and established service coverage targets to eliminate HCV as a public health threat by 2030. 10, 11 The new strategy calls for scale-up of HCV diagnosis and treatment by 2030 for a target coverage of 90% and 80%, respectively, and an 80% reduction in incidence by 2030. 10, 11 With DAA availability, Egypt has launched an ambitious new national treatment programme in 2014, [12] [13] [14] with the goal of reducing chronic HCV prevalence to <2% in 10 years, in line with global targets.
Egypt has also managed to attain price breaks of up to 99% in the cost of branded DAAs 15 and aimed to treat 250 000 persons annually up to 2020 as a first phase in their treatment programme.
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Against this background, and following success of the concept of treatment as prevention (TasP) for HIV infection, 16 we aimed in this study to assess the impact and implications of the concept of
TasP for HCV infection as demonstrated in an application for Egypt.
Specifically, we developed a dynamic forecasting mathematical model to (i) assess the impact of Egypt's treatment scale-up on HCV incidence using different scenarios of scale-up and sustainability, (ii) assess the treatment scale-up and sustainability that is required to achieve 90% reduction in HCV incidence by 2030 (a slight modification of the 80% global target) and (iii) assess the scale-up and sustainability that is required to achieve HCV elimination by 2030-where elimination is defined as an incidence rate <1 per 100 000 persons per year by 2030.
Our overarching goal is to examine whether HCV-TasP is a strategic prevention approach in a context of a generalized HCV epidemic, complementing primary prevention approaches of interventions such as injection safety, blood screening and infection control.
| MATERIALS AND METHODS

| Mathematical model
We constructed a deterministic dynamical mathematical model, based on extension of earlier models 17, 18 and modelling guidelines for best practice, 19 to describe HCV transmission in a given population-in this case the population of Egypt ( HCV natural history in the model is divided into three stages: primary acute infection, secondary acute infection and chronic infection.
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The model disaggregates Egypt's population into three age groups: children (1-14 years old), adults (15-59 years old) and elders (>60 years old). To account for heterogeneity in exposure risk, the model incorporates five risk groups, starting from lower to higher levels of exposure risk (one being the lowest and five being the highest). 
| Data sources and model fitting
We parameterized the model using current data for HCV transmission and natural history (Table 1 and Table S1 31 and these projections were reproduced by our model (Fig. S2 in SM) .
The model was fitted to HCV prevalence trend data using a nonlinear, least-square fitting method. This technique was implemented in MATLAB ® 32 using the Nelder-Mead simplex algorithm. 33 To fit the model to Egypt's trend data, the population-average exposure risk was assumed to vary during the epidemic. Further details on data sources and model fitting can be found in SM.
| Epidemiologic, programming and health economics measures
The impact and implications of Egypt's treatment programme were assessed through epidemiologic, programming and health economics measures. Chronic infection prevalence was projected along with incidence, defined as number of new infections per year, and incidence rate, defined as number of new infections per susceptible person per year.
Incidence or incidence rate reductions were estimated using two approaches, each for a specific purpose. In the first one, incidence reduction was assessed by comparing incidence at a given time with the incidence in 2010, before programme launch. This estimate was used to define targets such as the 90% incidence reduction by 2030.
In the second approach, incidence rate reduction was assessed by comparing incidence rate at a given time in the presence of intervention,
with that in the no-intervention counterfactual scenario. This estimate was used to quantify incidence rate reduction that is strictly attributed to the programme. Of note, the incidence rate in Egypt is on a trajectory of decline even in the absence of any treatment intervention ( Figure 2A ).
This necessitated this approach to disentangle incidence rate reduction attributed to the programme from that due to "natural" epidemic course.
Annual reduction in incidence rate was also calculated to assess progress year by year. This was calculated by comparing incidence rate Cost-effectiveness of HCV-TasP was defined as the cost to avert one infection. This measure was calculated by dividing cost of programme since its launch by number of infections averted in this time horizon. All costs were calculated in USD. We assumed a total cost of $900 per treatment, mainly covering branded DAAs direct costs. Following convention, we applied an annual discount rate of 3% on future expenditures. 
| Baseline scale-up scenario
We assumed 250 000 treatments annually between 2014 and 2020, in line with scale-up plan in Egypt. 12, 13 After 2020, no sustainability phase was assumed and the programme is halted. This scenario is the least ambitious for the programme.
| Scale-up and sustainability scenario
We assumed that the programme starts with the baseline scale-up scenario up to 2020, but then is followed by a sustainability phase from 2021 to 2030 in which the annual number of treatments is sustained at 250 000.
| Target 80% incidence reduction scenario
We assumed that the programme starts with the baseline scale-up scenario up to 2020, but then is followed by a sustainability phase from 2021 to 2030 in which the annual number of treatments is set at a level that can achieve 80% incidence reduction by 2030.
| Target 90% incidence reduction scenario
We assumed that the programme starts with the baseline scale-up scenario up to 2020, but then is followed by a sustainability phase from 2021 to 2030 in which the annual number of treatments is set at a level that can achieve 90% incidence reduction by 2030. 
| Elimination scenario
We assumed that the programme starts with the baseline scale-up scenario up to 2020, but then is followed by a sustainability phase from 2021 to 2030 in which the annual number of treatments is set at a level that can yield an incidence rate <1 per 100 000 persons per year by 2030. This is the most ambitious scenario explored here and would virtually eliminate HCV incidence in Egypt.
| Uncertainty and sensitivity analyses
We conducted multivariable uncertainty analyses to determine the ranges of uncertainty in incidence rate reduction and HCV-TasP effectiveness by 2030 with respect to variations in the model structural parameters including scale parameter of the risk-group gamma distribution, duration spent in a specific risk group, exponent parameter of the power-law function of exposure risk and degree of mixing assortativeness. We implemented 1000 model runs applying at each run Monte Carlo sampling from uniform probability distributions assuming 25% uncertainty around the point estimates (Table S1 in SM). Each set of sampled parameters was used to recalculate incidence rate reduction and HCV-TasP effectiveness by 2030. Means of calculated measures and associated 95% uncertainty intervals (UIs)
were calculated and reported for each scenario.
To assess how HCV-TasP effectiveness may potentially vary for settings at lower incidence rate than Egypt, we conducted a sensitivity analysis by calculating HCV-TasP effectiveness by 2030 as a function of incidence rate. This calculation was implemented using Egypt's model, but by lowering HCV population-average exposure risk to yield a lower incidence rate. Figure 2 shows model projections up to 2030 for the trend in HCV antibody prevalence among children, adults and elders compared to EDHS data (Figure 2A ), trend in HCV antibody prevalence in the total population ( Figure 2B ) and trend in HCV antibody incidence rate in the total population ( Figure 2C ). HCV prevalence was predicted to be in a trajectory of decline, even in the absence of mass treatment programme. While HCV prevalence in the total population was estimated at 9.3% in 2015, it was projected to decline to 5.8% by 2030. Similarly, while HCV incidence rate was estimated at 110 per 100 000 persons per year in 2015, it was projected to decline to 74 per 100 000 persons per year by 2030, a 33% reduction over this time horizon. Table 2 and Figure 3 show the predicted impact of the five programme scenarios among the total population of Egypt, and The impact of HCV-TasP was generically explored in settings at lower incidence rate than Egypt (Fig. S5 in SM) . Number of treatments required to avert one new infection by 2030 was found to increase steadily with lower incidence rate; for example, in a setting at half of Egypt's incidence rate, 20 treatments would be needed to avert one new infection by 2030.
| RESULTS
| DISCUSSION
HCV treatment is indicated at the individual level to prevent disease sequelae such as fibrosis, cirrhosis and liver cancer. Less obvious, The benefits of HCV-TasP were demonstrated for Egypt, the nation most historically affected by this virus. HCV incidence in this country was found to be on a trajectory of decline (Figure 2 ), but will continue at considerable level for decades if not controlled by interventions (Figure 3 ).
All explored scenarios achieved sizable if not immense impact on incidence and chronic infection prevalence. By 2030, incidence reduction ranged between 29% and 99%, programme-attributed incidence rate reduction ranged between 18% and 99%, and chronic infection prevalence reached as low as 2.8%-0.1% (Table 2 and Figure 3 ). The impact was also immediate with incidence rate reduction hovering around 10%
per year in the first few years of scale-up ( Figure 3) . By reaching virtually universal treatment coverage by 2030, 5.6 million people would have been treated, and nearly half a million infections averted (Table 2 ). For every 12 DAA treatments, one infection would be prevented by 2030, at direct drug costs of about $10 000 (Table 2 ; about three times per capita gross domestic product (GDP) 38 )
.
While these findings demonstrate the relevance of HCV-TasP in Egypt, our generic results for settings at lower incidence rate suggest that HCV-TasP should also be considered and examined as a potential intervention in other countries ( Egypt has been rapidly scaling up its DAA programme since its launch in 2014. More than 800 000 treatments have been administered by September 2016. 39 Treatment eligibility has been expanded to include all adults with chronic infection. 14, 39 Treatment is being provided through 54 designated government centres and through 50 additional health insurance hospital centres. 39 Our results indicate,
however, that the targets of reducing chronic infection prevalence to <2% in 10 years, and reducing incidence by 90% by 2030, cannot be achieved unless the number of annual treatments reaches 365 000 and is sustained at this level for at least a decade. The cumulative direct drug costs may reach as much as $5 billion by 2030, which is a large sum for a developing nation like Egypt, but this cost is minimal when As Egypt expands its programme, screening for HCV will play a critical role. Only 7.1% of Egyptians 1-59 years of age reported being ever tested for HCV in the 2015 EDHS, 6 and it was estimated recently that <25% of those chronically infected are aware of their infection. 38 Without active case finding, the programme will not be able to function at its capacity and future potential. Screening can be expanded through awareness campaigns and fixed and mobile testing units and should be targeting initially birth cohorts and geographic localities with higher HCV prevalence. 41 Encouragingly, the Egypt Ministry of Health and Population plans to launch a national screening campaign of 10 million Egyptians. 39, 42 There are several limitations in our study. Our study focused on HCV-TasP, and we did not model other prevention approaches, such as injection safety, nor did we study synergies of interventions. We assumed that all chronically infected persons could be treated, but treatment may not be recommended for all patients. For example, vertical transmission is not an insignificant mode of transmission in Egypt, 43 but current guidelines do not recommend treatment of pregnant women. We did not incorporate previous treatments (prior to 2014) by old regimen, but treatment coverage has been very low up to initiation of the DAA programme. 6, 38 Our estimated impact of treatment is possibly conservative, as we did not incorporate disease-related mortality. However, the relative risk of mortality with HCV infection is not large enough to impact significantly our projections. 44 For simplicity, we assumed that the duration spent in each risk group is age independent, but this assumption is not likely to affect our results, as exposure risk is already age-dependent in our model, thereby capturing implicitly a duration variation effect. Most HCV biological parameters found in the literature and used in the model are from studies conducted on PWID, and it is unknown whether these are generalizable to the general population. We assumed that HCV transmission probability in acute infection does not vary by symptoms, but this is not likely to affect our results as the proportion who are symptomatic is small and acute infection lasts for only few months. In the absence of data, we assumed an assortativeness in mixing between risk groups at a level similar to that used in HIV models, 45 but variation in this parameter through sensitivity analysis did not affect our results (not shown).
We used an elaborate mathematical model to capture HCV transmission dynamics, but projections can depend on model structure and quality of input data. To account for uncertainties, we conducted a multivariable uncertainty analysis which affirmed our findings (Fig.   S4 ). Incidence projections were generated by fitting current trends, but future incidence can be influenced by factors that are difficult to predict, such as scale-up of other interventions. As the programme is scaled up in Egypt, it would be important to collect primary data that may help estimate incidence as part of a monitoring and evaluation component of the programme, and compare and validate results with modelling estimates. Egypt is suited for such monitoring and evaluation framework given the existing capacity for epidemiologic surveillance and study infrastructure.
In conclusion, we assessed the implications of various scenarios 
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